Sogroya® (somapacitan-beco) is a once-weekly treatment option, offering an alternative to once-daily therapy, which may help ...
DENVER -- A daily, single-tablet combination of bictegravir and lenacapavir (Yeztugo) was noninferior to complex multi-tablet ...
Walgreens is wading into the self-pay GLP-1 space, going head-to-head with telehealth subscription offerings. | Walgreens is wading into the self-pay GLP-1 space, going head-to-head with telehealth ...
TG Therapeutics reported $594M in 2025 U.S. BRIUMVI sales, a 90% YoY increase, and guides for $825–$850M in 2026. Click here ...
Tardigrades, commonly known as water bears, may be better suited by a new name: Tardiguardians of the Galaxy. Unlike the ...
Tiny pits, webbing patterns, and a dusting of nanoparticles are not what most people picture when they think about farming.
Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at ...
At a live Case-Based Roundtable event during the 2025 American Society of Hematology (ASH) annual meeting, Joshua Richter, MD, discussed the evolving role of selinexor (Xpovio) in ...
The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...
Physician-scientist and acclaimed adipose tissue biologist to advise on first-in-class, oral MS 001 for obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results